LOS ANGELES, Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE: FNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Paragon filed an 8-K with the SEC on July 30, 2024. The filing stated, "On July 30 ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. (“Paragon 28” or “the Company”) (NYSE: FNA). Investors who purchased Paragon 28 securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/FNA. Investigation Details On July 30, 2024, Paragon 28 filed a current report on Form 8-K with the SEC, and stated that “On ...

财务数据和关键指标变化 - 第一季度全球收入创纪录达6,110万美元,同比增长17.4%,达到公司4月4日预报的上限 [10] - 美国业务第一季度收入为5,110万美元,同比增长13.5% [11] - 国际业务第一季度收入为1,000万美元,同比增长42.2%,以恒定汇率计算增长42.5% [12] - 毛利率为80%,较上年同期下降2.9个百分点,主要由于供应商价格上涨和产品及地理结构变化 [16] 各条业务线数据和关键指标变化 - 美国业务方面,销售代表人数增加6%至261人,生产性销售代表的生产率提高8% [11] - 美国客户群增长12%至2,275名外科医生 [11] - 国际业务增长主要来自英国和澳大利亚 [12] 各个市场数据和关键指标变化 - 美国业务收入增长13.5% [11] - 国际业务收入增长42.2%,以恒定汇率计算增长42.5% [12] 公司战略和发展方向及行业竞争 - 公司持续专注于创新,2024年第一季度推出6款新产品,主要集中在高增长的足踝细分市场,如骨囊肿、软组织和微创手术 [12][13] - 公司产品线的持续创新和推广有助于公司在快速增长的细分市场保持领先地位,为可持续长期增长奠定基础 [12][14] - 公司在国际市场的投资和布局取得良好进展,为公司的全球化发展奠定了基础 [24][25] 管理层对经营环境和未来前景的评论 - 公司对2024年全年业绩目标保持信心,维持此前公布的2.49亿美元至2.59亿美元的收入指引 [20] - 公司将继续投资商业和教育机会,以充分释放新产品和现有产品在美国和国际市场的潜力 [14][15] - 公司预计2024年EBITDA实现正值的时间略有推迟,但将继续优化成本结构,提高运营效率 [18][19] 问答环节重要的提问和回答 问题1 **Matthew O'Brien 提问** 对于公司维持全年收入指引的原因,是否存在国内或国际市场的担忧,以及未来国内外业务增长的预期 [22][23][24][25] **Albert DaCosta 回答** 公司对全年收入目标充满信心,国内外业务均保持良好增长势头,尤其是国际业务增速较快,公司将继续加大国际市场的投资和布局 [23][24][25] 问题2 **Craig Bijou 提问** 公司加大销售团队投资的原因和考虑,以及未来2-3年的发展计划 [38][39][40] **Albert DaCosta 回答** 公司在新产品推出时会带来市场机会,公司会审慎评估并选择合适的销售人才加入,以确保销售团队的临床专业性和公司文化契合度,为公司长期发展提供支持 [38][39][40] 问题3 **Mike Matson 提问** 公司是否有一次性的销售费用支出,未来销售费用是否会有所下降 [45][46][47][48][49] **Krissy Wright 回答** 公司预计销售费用占收入比重将逐季下降,随着收入增长而得到较好的杠杆 [47][48][49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3170186 (State or other jurisdiction of ...

财务情况 - 公司发布了2024年第一季度未经审计的净收入预览[3] - 公司确认了截至2024年12月31日的年度净收入指引[11] 高管变动 - 公司首席财务官Steve Deitsch宣布辞职，将由Kristina Wright担任临时首席财务官[6] - Kristina Wright曾在Cleerly担任首席财务官，现在担任公司的临时首席财务官[8]

OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where h ...

Paragon 28, Inc. (FNA) , a leading innovator in orthopedic solutions, has unveiled its latest breakthrough — the Grappler R3INFORCE Extraosseous Repair System. This system is set to advance syndesmotic injury repair, marking significant progress for Paragon 28 in terms of improving patient outcomes. Addressing Syndesmotic Instability The Grappler R3INFORCE System is specifically designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and hig ...

股价表现 - Paragon 28, Inc. (FNA)股价在最近一个交易日上涨了16.2%，收盘价为$11.91，这可能是由于交易量较大，交易的股票数量比一般交易日要多[1] - Paragon 28的股价上涨受到投资者乐观情绪的推动，公司最近宣布了2023年第四季度业绩，其中营收同比增长了17.6%，国际收入同比增长了43.1%，公司各个足踝部门都实现了稳健平衡的增长[2] 季度预期 - 预计该公司在即将发布的季度报告中每股亏损$0.11，与去年同期相比没有变化，预计营收为$58.89百万美元，同比增长13.2%[3]

1 4Q and Full Year 2023 Update February 29, 2024 Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28's potential to shape a better future for foot and ankle patients and its estimated net revenue for full year 2024. You are cautioned not to place undue reli ...

Paragon 28, Inc. (NYSE:FNA) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Matthew Brinckman - Senior Vice President, Strategy and IR Albert DaCosta - Chairman and CEO Steve Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America George Sellers - Stephens, Inc. Dave Turkaly - Citizens Bank Mike Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Justin Lin - William Blair Operator Good afternoo ...